Clinical observation of the relation between the HBeAg and HBV-related hepatocellular carcinoma

Objective To study the virus-related factors, biochemical differences in the HBeAg-negative and HBeAg-positive patients with primary liver cancer, and to explore the clinical significance.Methods Retrospective analysis of merger of 220 cases of hospitalized HBV infection with primary liver cancer in the First Affiliated Hospital of West China from January 2009 to November 2010, and were divided into HBeAg-positive and HBeAg-negative groups.Analysis of AFP level, liver function levels, HBV DNA quantitative, targets liver histology differences of the two groups were made.Results 195 cases of HBeAg-negative primary liver cancer accounting for 89%;25 cases of HBeAg-positive hepatocellular carcinoma, accounting for 11%.HBeAg-positive group HBV DNA quantitative was significantly higher than the mean of the number of HBeAg negative group (t= 2.01, P<0.05) ;HBeAg-positive group stage four liver fibrosis ratio of 32%, was significantly higher than the HBeAg negative group of 21% (χ2= 9.5, P= 0.049) .The AFP level and other indicators of liver function of the two groups had no statistically significant difference.Conclusion The incidence of HBeAg-positive HCC was higher than that of HBeAg-negative, which was inconsistent with the domestic Zou Chuanxin report.Compared with HBeAg-negative primary liver cancer, liver damage in HBeAg-positive patients was commonly observed with severe liver histology, combined with portal cancer, and cirrhosis of the liver and making the prognosis even worse.HBeAg-negative patients with hepatocellular carcinoma was higher than the HBeAg-positive.